We are happy to spread word of?Pathios Therapeutics becoming a clinical-stage company. This morning, the company announced that the first patient was dosed in a Phase 1/2 clinical trial of its lead development candidate, PTT-4256. The compound is a first-in-class, potent and selective inhibitor of GPR65, an acid sensing a G protein-coupled receptor. PTT-4256 leverages a unique therapeutic strategy in the fight against solid tumors by working to counteract the #immunosuppressive polarization of #immune cells in the #tumor #microenvironment. Preclinical studies have demonstrated promising anti-tumor activity and we are excited to see what plays out in the clinic. Read more details in the press release here: https://lnkd.in/ewmUvq9a
